Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NISCH | Q9Y2I1 | 2/20 | 0.64 |
| ▸ | MTOR | P42345 | 1/20 | 0.63 |
| ▸ | ADK | P55263 | 1/20 | 0.63 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.56 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.56 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.51 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.51 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.51 |
| ▸ | CYP19A1 | P11511 | 1/20 | 0.51 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.51 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.51 |
| ▸ | PDE3B | Q13370 | 1/20 | 0.50 |
| ▸ | PDE3A | Q14432 | 1/20 | 0.50 |
| ▸ | PKM | P14618 | 1/20 | 0.43 |
| ▸ | MAPK14 | Q16539 | 3/20 | 0.43 |
| ▸ | GCGR | P47871 | 1/20 | 0.43 |
| ▸ | NPC1 | O15118 | 1/20 | 0.43 |
| ▸ | RAB9A | P51151 | 1/20 | 0.43 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.43 |
| ▸ | PDE4A | P27815 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL28346045 | 0.98 | NISCH (0.62) | NISCHMTORADKALDH1A1KDM4E | |
| Bromide SCHEMBL28348957 | 0.98 | NISCH (0.62) | NISCHMTORADKALDH1A1KDM4E | |
| SCHEMBL29160555 | 0.92 | NISCH (0.56) | NISCHMTORADKALDH1A1KDM4E | |
| SCHEMBL29160561 | 0.92 | NISCH (0.56) | NISCHMTORADKALDH1A1KDM4E | |
| Ethylene Glycol SCHEMBL27721441 | 0.91 | NISCH (0.55) | NISCHMTORADKALDH1A1KDM4E | |
| Dimethyl Sulfoxide SCHEMBL27877985 | 0.89 | NISCH (0.58) | NISCHMTORADKALDH1A1KDM4E | |
| SCHEMBL1386454 | 0.89 | CYP1A2 (0.55) | NISCHMTORADKALDH1A1KDM4E | |
| SCHEMBL722191 | 0.89 | NISCH (0.78) | NISCHMTORADKALDH1A1KDM4E | |
| SCHEMBL862114 | 0.86 | NISCH (0.75) | NISCHMTORADKALDH1A1KDM4E | |
| SCHEMBL2049365 | 0.81 | NISCH (0.52) | NISCHMTORADKALDH1A1KDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 137 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250228242-A1 | PROTEIN AGGREGATION INHIBITING COMPOUNDS FOR PLANT DISEASE CONTROL | MAX-PLANCK-Gesellschaft zur Förderung der Wissenschaften e.V. (DE) | 2025-07-17 | — | — | US | claimed |
| CN-117567509-A | Gold (I) gefitinib derivative and preparation method and application thereof | 华中科技大学同济医学院附属同济医院 | 2024-02-20 | — | — | CN | claimed |
| CN-101735217-B | Application of imidazole [4,5-f][1,10] phenanthroline and derivative thereof to preparation of antineoplastic drug | UNIV GUANGDONG PHARM | 2012-09-26 | — | — | CN | claimed |
| CN-101863894-B | Tanshinone II A derivative and preparation method and application thereof | UNIV GUANGDONG PHARM | 2012-07-18 | — | — | CN | claimed |
| CN-101863894-A | Tanshinone II A derivative and preparation method and application thereof | GUANGDONG PHARMACEUTICAL UNIVERSITY | 2010-10-20 | — | — | CN | claimed |
| CN-101735217-A | Application of imidazole [4,5-f][1,10] phenanthroline and derivative thereof to preparation of antineoplastic drug | UNIV GUANGDONG PHARM | 2010-06-16 | — | — | CN | claimed |
| CN-101379065-A | Imidazopyridine derivatives inhibiting protein kinase activity, method for the preparation thereof and pharmaceutical composition containing same | CRYSTALGENOMICS INC (KR) | 2009-03-04 | — | — | CN | claimed |
| US-20250228242-A1 | PROTEIN AGGREGATION INHIBITING COMPOUNDS FOR PLANT DISEASE CONTROL | MAX-PLANCK-Gesellschaft zur Förderung der Wissenschaften e.V. (DE) | 2025-07-17 | — | — | US | disclosed |
| US-20250188072-A1 | COMPOUNDS FOR TREATMENT OF CANCER | UNIVERSITY OF TENNESSEE RESEARCH FOUNDATION (US) | 2025-06-12 | — | — | US | disclosed |
| US-20250127030-A1 | ORGANIC ELECTROLUMINESCENT MATERIALS AND DEVICES | UNIVERSAL DISPLAY CORPORATION (US) | 2025-04-17 | — | — | US | disclosed |
| US-12187720-B2 | Compounds for treatment of cancer | UNIVERSITY OF TENNESSEE RESEARCH FOUNDATION (US) | 2025-01-07 | — | — | US | disclosed |
| US-12171138-B2 | Organic electroluminescent materials and devices | UNIVERSAL DISPLAY CORPORATION (US) | 2024-12-17 | — | — | US | disclosed |
| CN-117642404-A | Small molecule modulators of glucocerebrosidase activity and uses thereof | 凡况生化公司 | 2024-03-01 | — | — | CN | disclosed |
| WO-1999041235-A1 | FARNESYL TRANSFERASE INHIBITORS | ASTRAZENECA UK LIMITED (GB) | 1999-08-19 | — | — | WO | disclosed |
| WO-1999020612-A1 | IMIDAZOLE DERIVATIVES AND THEIR USE AS FARNESYL PROTEIN TRANSFERASE INHIBITORS | ASTRAZENECA UK LIMITED (GB) | 1999-04-29 | — | — | WO | disclosed |
| CN-1138326-A | N-substituted aryl-trifluoromethyl imidazoles | BAYER AG (DE) | 1996-12-18 | — | — | CN | disclosed |
| US-4314844-A | FUNGICIDES | ROHM AND HAAS COMPANY (US) | 1982-02-09 | — | — | US | disclosed |
| US-4301170-A | ANTIOBESITY AGENT | SANDOZ, INC. (US) | 1981-11-17 | — | — | US | disclosed |
| EP-0011115-A1 | Antiinflammatory 2-substituted-1H-phenanthro(9,10-d)imidazoles, their preparation and pharmaceutical compositions containing them | E.I. DU PONT DE NEMOURS AND COMPANY (US) | 1980-05-28 | — | — | EP | disclosed |
| EP-0002649-A2 | 1-Dimethyl-substituted alkyl-2- or 4-substituted phenylimidazoles, their production and their use as anti-obesity agents | SANDOZ AG (CH) | 1979-06-27 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12187720-B2 | Compounds for treatment of cancer | KLK3, BRDT, ACP3 | NISCH 3272/4885MTOR 1294/4885ADK 2226/4885 |
| US-20250127030-A1 | ORGANIC ELECTROLUMINESCENT MATERIALS AND DEVICES | OSBP2, EML4, OSBP | NISCH 1362/4885MTOR 2533/4885ADK 2791/4885 |
| US-12171138-B2 | Organic electroluminescent materials and devices | OSBP2, EML4, OSBP | NISCH 1349/4885MTOR 2484/4885ADK 2761/4885 |
| US-20250228242-A1 | PROTEIN AGGREGATION INHIBITING COMPOUNDS FOR PLANT DISEASE CONTROL | APP, APBA1, PRNP | NISCH 3844/4885MTOR 1273/4885ADK 2513/4885 |
| US-20250188072-A1 | COMPOUNDS FOR TREATMENT OF CANCER | KLK3, BRDT, ACP3 | NISCH 3272/4885MTOR 1294/4885ADK 2226/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.